VYNE Therapeutics (VYNE) Q1 2026 earnings summary

Executive summary

• Focused on developing therapies for inflammatory and immune-mediated conditions, with a pipeline centered on BET inhibitors licensed from Tay Therapeutics.

• Suspended and winding down R&D activities in anticipation of a merger with Yarrow Bioscience, which will become the primary business post-merger.

• Entered into a merger agreement with Yarrow, expected to close in Q3 2026, with a concurrent $100M pre-closing financing and a special cash dividend of $14.5–$16.5M to shareholders.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $24.9M as of March 31, 2026; no outstanding debt.

• Net loss for Q1 2026 was $3.6M, a 58% improvement year-over-year from $8.6M in Q1 2025.

• Operating expenses decreased 58% year-over-year to $3.9M, driven by an 87% reduction in R&D expenses.

• Royalty revenues were $0.1M, down from $0.2M in Q1 2025.

Outlook and guidance

• Existing cash is expected to fund operations through the anticipated merger closing and at least 12 months from the reporting date.

• If the merger is not completed, strategic alternatives or liquidation may be pursued; additional capital would be required to continue product development.